Medtronic: Renal Denervation Lowered Blood Pressure in Hypertension

Medtronic plc said new data showed renal denervation with the Medtronic Symplicity Renal Denervation System significantly reduced blood pressure in uncontrolled hypertension patients out to three years.

The study showed RDN led to significant and clinically meaningful reductions in blood pressure that were sustained out to three years post-procedure, with more patients achieving BP below 140 mmHg, while those at very high blood pressure levels experienced drops into lower risk ranges, Medtronic said.

Regardless of the number of anti-hypertensive medications prescribed, a majority of patients with the highest blood pressure showed significant drops at three years, Medtronic said.

“In the largest real-world study of patients receiving renal denervation, we are seeing significant and clinically meaningful reductions in both office and 24-hr blood pressure sustained out to three years post-procedure, which demonstrates the durability of RDN,” said Felix Mahfoud, cardiologist at Saarland University Medical Center in Homburg, Germany, who presented the data during the PCR e-Course 2020 meeting.

The Global SYMPLICITY Registry is the largest study documenting the long-term safety and effectiveness of the Medtronic renal denervation systems in a real-world setting in patients with uncontrolled hypertension. To date, the registry has enrolled more than 2,860 patients treated with RDN and includes three-year follow-up for more than 2,500 patients.

https://www.marketscreener.com/MEDTRONIC-PLC-20661655/news/Medtronic-Says-Data-Show-Renal-Denervation-Lowered-Blood-Pressure-in-Patients-with-Hypertension-30825460/